News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC
Oscar Arrieta/X
May 17, 2025, 12:09

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

Oscar Arrieta, Head of the Thoracic Oncology Unit at National institute of Oncology in Mexico, shared a post on X:

“We reported in Nature Communications, this phase 2 trial, the combination of alectinib and bevacizumab (ALEK-B) in patients with advanced ALK rearranged NSCLC from National Cancer Institute, the 12-month PFS rate was 97.1% The 36-month PFS and OS rates were 64.2% and 87.9% respectively.
The ORR was 100%, and the 36-month icPFS rate was 87.8%. Grade 3–4 adverse events occurred in 46.3% of patients, most commonly proteinuria and hepatotoxicity, QoL significantly improved from baseline at 12 months and was maintained through 36 months. These findings support the efficacy and safety of alectinib plus bevacizumab and justify further investigation in ALK-rearranged NSCLC.”

Title: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Authors: Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F. Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell

Read The Article at Nature Communications.

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC

More Posts featuring NSCLC.

Alexandra Garcilazo-Reyes ALK-rearranged NSCLC Andres F. Cardona cancer David Dávila-Dupont Eduardo Rios-Garcia Enrique Caballé-Pérez Graciela Cruz-Rico Jordi Remon Luis Cabrera-Miranda Luis Lara-Mejía Maritza Ramos-Ramírez National Cancer Institute Nature Communications NSCLC OncoDaily Oncology Oscar Arrieta Rafael Rosell
Special Coverage
Blog
May 17, 2025, 12:09
Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC
Blog
May 17, 2025, 11:55
Jordi Remon Highlights EORTC Lung Cancer Group’s Spring Meeting in Genova
Science
May 17, 2025, 11:48
Raffaele Colombo: The Therapeutic Window of Antibody-Drug Conjugates
Blog
May 17, 2025, 11:40
Sachin Jain: Dismantling Medicine’s White Wall of Silence
Blog
May 17, 2025, 11:33
Peter Pisters: MD Anderson and Texas Children’s Launch Kinder Children’s Cancer Center to End Childhood Cancer
Blog
May 17, 2025, 11:26
Matthew Zachary: Remembering Ryan O'Donoghue - A Giant in Cancer Advocacy
Blog
May 17, 2025, 10:33
HYPART Trial: Testing 1-Week vs. 2-Week Radiotherapy for High-Risk Breast Cancer at ESMO Breast 2025
Science
May 17, 2025, 10:22
Nelson Dusetti Shared New Article on E-cadherin's Function in Pancreatic Cancer Cell Invasion
Blog
May 17, 2025, 10:22
Iker Huerga: Pathos AI Secures $365M in Series D financing to Transform Oncology Drug Development
Career
May 17, 2025, 10:19
Stephanie Graff: Honored to Deliver Comments at UMKC School of Medicine Class of 2025 Hooding Ceremony
Blog
May 17, 2025, 10:16
Elizabeth F. Franklin: Approximately 60-70% of Cancer Deaths Occur in Cancers That Do Not Currently Have Screening Tests
Insight
May 17, 2025, 10:11
Mohan Uttarwar: 19 of our abstracts have been accepted at ASCO 2025 Annual Meeting